GlaxoSmithKline exercised its option to license Ionis Pharmaceuticals’ antisense medicines for people with chronic hepatitis B virus (CHB) infection following positive Phase 2 results.    As a part of the licensing agreement, Ionis is eligible to receive license fees and milestone payments up to $262 million, including a $25 million license fee. In addition, Ionis is also eligible to receive tiered royalties in the low double digits on net sales. GSK is now responsible for all development, reg...